Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response

Eur J Haematol. 2014 Mar;92(3):268-70. doi: 10.1111/ejh.12240. Epub 2014 Jan 10.

Authors

Maxi Wass¹, Timo Behlendorf, Bärbel Schädlich, Anja Mottok, Andreas Rosenwald, Hans-Joachim Schmoll, Karin Jordan

Affiliation

¹ Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.

PMID: 24330038
DOI: 10.1111/ejh.12240

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anaplastic Lymphoma Kinase
Crizotinib
Fatal Outcome
Female
Gene Expression Regulation, Neoplastic*
Humans
Ki-1 Antigen / metabolism
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / metabolism*
Perforin / metabolism
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-myc / metabolism
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Receptor Protein-Tyrosine Kinases / metabolism*
Recurrence
Syndecan-1 / metabolism
Treatment Outcome

Substances

Ki-1 Antigen
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-myc
Pyrazoles
Pyridines
Syndecan-1
Perforin
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases